What are the differences between how AI systems handle JavaScript-rendered or interactively hidden content compared to ...

Replit tackles the slop problem through a mix of specialized prompting, classification features built into its design systems ...

Replit CEO Amjad Masad says CEOs are showing up to meetings with prototypes, and product managers may just be "some of the ...

Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of Ollama (with its variety of LLM choices). Typically, you would connect to ...

IT: Welcome to Derry, starring Bill Skarsgård and inspired by Stephen King’s classic novel, premieres on streaming and cable on Sunday. Forbes‘IT: Welcome To Derry’ Rotten Tomatoes Reviews: Does ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Despite the relentless insistence of tech’s grifters, AI is not industrially inevitable – or even sustainable. Which is why it is time to push back Bad news, baby. The New Yorker reports the rapid ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...